| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial MP Manns, JG McHutchison, SC Gordon, VK Rustgi, M Shiffman, ... The Lancet 358 (9286), 958-965, 2001 | 8338 | 2001 |
| Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C JG McHutchison, SC Gordon, ER Schiff, ML Shiffman, WM Lee, VK Rustgi, ... New England Journal of Medicine 339 (21), 1485-1492, 1998 | 4580 | 1998 |
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance D Ge, J Fellay, AJ Thompson, JS Simon, KV Shianna, TJ Urban, ... Nature 461 (7262), 399-401, 2009 | 4551 | 2009 |
| Telaprevir for previously untreated chronic hepatitis C virus infection IM Jacobson, JG McHutchison, G Dusheiko, AM Di Bisceglie, KR Reddy, ... New England Journal of Medicine 364 (25), 2405-2416, 2011 | 3289 | 2011 |
| Genetic variation in IL28B and spontaneous clearance of hepatitis C virus DL Thomas, CL Thio, MP Martin, Y Qi, D Ge, C O’hUigin, J Kidd, K Kidd, ... Nature 461 (7265), 798-801, 2009 | 2722 | 2009 |
| Sofosbuvir for previously untreated chronic hepatitis C infection E Lawitz, A Mangia, D Wyles, M Rodriguez-Torres, T Hassanein, ... New England Journal of Medicine 368 (20), 1878-1887, 2013 | 2442 | 2013 |
| Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Afdhal, S Zeuzem, P Kwo, M Chojkier, N Gitlin, M Puoti, ... New England Journal of Medicine 370 (20), 1889-1898, 2014 | 2163 | 2014 |
| Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study P Marcellin, E Gane, M Buti, N Afdhal, W Sievert, IM Jacobson, ... The Lancet 381 (9865), 468-475, 2013 | 2103 | 2013 |
| Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection JG McHutchison, EJ Lawitz, ML Shiffman, AJ Muir, GW Galler, J McCone, ... New England Journal of Medicine 361 (6), 580-593, 2009 | 1803 | 2009 |
| Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Afdhal, KR Reddy, DR Nelson, E Lawitz, SC Gordon, E Schiff, ... New England Journal of Medicine 370 (16), 1483-1493, 2014 | 1718 | 2014 |
| Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis KV Kowdley, SC Gordon, KR Reddy, L Rossaro, DE Bernstein, E Lawitz, ... New England Journal of Medicine 370 (20), 1879-1888, 2014 | 1517 | 2014 |
| Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C T Poynard, J McHutchison, M Manns, C Trepo, K Lindsay, Z Goodman, ... Gastroenterology 122 (5), 1303-1313, 2002 | 1492 | 2002 |
| Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options IM Jacobson, SC Gordon, KV Kowdley, EM Yoshida, M Rodriguez-Torres, ... New England journal of medicine 368 (20), 1867-1877, 2013 | 1436 | 2013 |
| Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection JG McHutchison, GT Everson, SC Gordon, IM Jacobson, M Sulkowski, ... New England Journal of Medicine 360 (18), 1827-1838, 2009 | 1430 | 2009 |
| Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection JJ Feld, IM Jacobson, C Hézode, T Asselah, PJ Ruane, N Gruener, ... New England Journal of Medicine 373 (27), 2599-2607, 2015 | 1360 | 2015 |
| Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C JG McHutchison, M Manns, K Patel, T Poynard, KL Lindsay, C Trepo, ... Gastroenterology 123 (4), 1061-1069, 2002 | 1329 | 2002 |
| Telbivudine versus lamivudine in patients with chronic hepatitis B CL Lai, E Gane, YF Liaw, CW Hsu, S Thongsawat, Y Wang, Y Chen, ... New England Journal of Medicine 357 (25), 2576-2588, 2007 | 1193 | 2007 |
| Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C GL Davis, JB Wong, JG McHutchison, MP Manns, J Harvey, J Albrecht Hepatology 38 (3), 645-652, 2003 | 1150 | 2003 |
| Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection GR Foster, N Afdhal, SK Roberts, N Bräu, EJ Gane, S Pianko, E Lawitz, ... New England Journal of Medicine 373 (27), 2608-2617, 2015 | 1064 | 2015 |
| Sofosbuvir and ribavirin in HCV genotypes 2 and 3 S Zeuzem, GM Dusheiko, R Salupere, A Mangia, R Flisiak, RH Hyland, ... New England Journal of Medicine 370 (21), 1993-2001, 2014 | 1037 | 2014 |
